About this document
Jop 19 00335 by Mireya Carrasco is a document available to read on EtoBox.
Autologous stem-cell transplantation (ASCT) remains a crucial treatment for multiple myeloma (MM) despite advancements in novel therapies. Studies indicate that ASCT can enhance treatment responses and survival rates, particularly when combined with immunomodulatory agents and proteasome inhibitors. The review discusses the importance of timing, patient selection, and the evolving role of ASCT in conjunction with new therapeutic agents to optimize patient outcomes.
- Author
- Mireya Carrasco
- Language
- EN